November 22, 2021 7:50am
The escape begins to a shortened holiday week, U.S. markets will be closed Thursday on Thanksgiving Day. The stock market closes early at 1 p.m. ET on Friday.
Pre-open indications: 4 SELLs, 5 BUY sand 1 Pump (or No Promote)
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Dow futures are UP +0.25% (+80 points), S&P futures are UP +0.30% (+14 points) and NASDAQ futures are UP +0.40% (+67 points)
Stock futures rose in early but were percentage declining in pre-market trading on Monday
European stocks were mixed
Asia-Pacific stocks were mixed as China kept its benchmark lending rate unchanged.
Henry’omics:
Stocks have a track record of posting gains in Thanksgiving week, which will potentially set the stage for I believe a coming down-draft.
A market-moving (volatility) event this week will be President Biden’s nomination for the next Federal Reserve chief.
If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
Friday’s evening’s recap: “Friday’s diving is more than a watersport” … https://www.regmedinvestors.com/articles/12192
Q4: November, 3 positive and 12 negative close to date
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining SELL with a Pump or No Promote:
Biostage (BSTG) closed down -$0.39 with 8.625 shares traded after Thursday’s $0.00 with 17 shares traded after Wednesday 2,889 shares traded, Tuesday’s +$0.39 to $2.99 after last Monday’s FLAT at $2.60 with 35 shares traded.
- Earnings release: Biostage (BSTG) had a net loss of -$800 K, or -$0.80, a $200 K decrease in grant income and a cash position of $2 m—still with NO clinical trial with a 2-year-old IND. Add in some legal negligence ... where its insurance carrier will NOT cover the terminal death suit filed.
What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
Probabilities versus aftermarket/pre-open share pricing indication moves:
SELL:
Regenxbio (RGNX) closed up again +$1.51 to $33.51 after Thursday’s +0.51 to $32.00, Wednesday’s -$0.35 to $31.49, Tuesday’s $31.84 and last Monday’s $31.72 with a negative -$0.04 or -0.11% pre-open indication.
BUY:
AxoGen (AXGN) closed down -$0.37 to $9.76 with a positive +$0.07 or +0.76 pre-open indication. Chart says BUY post deep trough … in my view.
bluebird bio (BLUE) closed down -$0.21 to $10.70 with a positive +$0.83 or +7.76% pre-open indication as the FDA has accepted the Biologics License Application (BLA) for betibeglogene autotemcel (beti-cel) for priority review. Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions.
CRISPR Therapeutics (CRSP) closed down again -$0.53 to $82.44 after Thursday’s -$3.11 to $82.97, Wednesday’s -$0.50, Tuesday’s +$1.50 and last Monday’s -$3.85 with a positive +$0.56 or +0.68% pre-open indication.
Global Blood Therapeutics (GBT) closed down -$1.06 to $31.41 with a positive +$0.59 or +1.88% pre-open indication after multiple major dives.
Intellia Therapeutics (NTLA) closed down -$5.42 to $129.48 after Thursday’s +$0.50 to $134.90, Wednesday’s $134.40, Tuesday’s $137.50 and last Monday’s $133.54 with a positive +$0.22 or +0.17% pre-open indication
SELL into Strength:
Ultragenyx (RARE) closed up $1.93 to $79.32 with a positive +$2.06 or +2.60% pre-open indication.
Applied Genetic Technologies (AGTC) closed down -$0.12 to $2.60 after Thursday’s +$0.06 to $2.72 and Wednesday’s +$0.29 to $2.66 with a positive +$0.04 or+1.54% pre-open indication.
Sangamo Therapeutics (SGMO) closed down again -$0.25 to $9.07 after Thursday’s -$0.20 to $9.32, Wednesday’s -$0.28 to $9.52 after Tuesday’s $9.80 and Monday’s $9.82 with a positive +$0.07 or +0.77% pre-open indication.
The BOTTOM LINE: I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
